London close: Stocks slip as US non-farm payrolls undershoot
6th Sep 2024 15:45
(Sharecast News) - London stocks ended lower on Friday, as disappointing US jobs data weighed on investor sentiment.
Read moreIndivior CUD study fails to meet primary and secondary endpoints
4th Sep 2024 08:53
(Sharecast News) - Drugmaker Indivior said on Wednesday that the primary and secondary endpoints of Aelis Farma's clinical Phase 2B study of AEF0117 use in participants with cannabis use disorder had not been met.
Read moreLondon close: Stocks mixed on tsunami of updates, US GDP data
25th Jul 2024 15:27
(Sharecast News) - London stocks closed with mixed results on Thursday as investors processed faster-than-anticipated economic growth in the United States, following a heavy flow of corporate announcements earlier in the day.
Read moreIndivior shares rebound on $100m buyback plan
25th Jul 2024 08:47
(Sharecast News) - Indivior's share price surged on Thursday after the pharma group announced plans for $100m share buyback following a strong first-half performance, with second-quarter revenues in line with recent guidance.
Read moreLondon close: Stocks mixed as UK inflation holds steady
17th Jul 2024 12:28
(Sharecast News) - London stocks ended mixed on Wednesday as the latest inflation data came in slightly higher than anticipated, casting doubt on a potential interest rate cut in August.
Read moreLondon close: Stocks slip as investors digest Powell's comments
9th Jul 2024 15:24
(Sharecast News) - London stocks ended in negative territory on Tuesday, driven by concerns over a decline in retail sales and the impact of comments from US Federal Reserve chair Jerome Powell.
Read moreIndivior shares plummet on profit warning, product discontinuation
9th Jul 2024 07:39
(Sharecast News) - Pharma group Indivior saw shares plummet on Tuesday after it issued a profit warning for 2024 on the back of "adverse market dynamics" affecting its Sublocade treatment, and announced it was discontinuing its Perseris product.
Read moreIndivior reports first-quarter growth, confirms plans to shift main listing
25th Apr 2024 08:56
(Sharecast News) - Addiction treatment specialist Indivior reported double-digit net revenue growth for the first quarter on Thursday, with total net revenue rising 12% year-on-year to $284m, as it confirmed its intention to shift its primary listing to the United States.
Read moreIndivior receives settlement approval for antitrust litigation
29th Feb 2024 09:47
(Sharecast News) - Pharmaceuticals business Indivior has received final court approval for a landmark settlement in an antitrust multi-district litigation with the direct purchaser class.
Read moreLondon close: Stocks rise amid raft of solid earnings
22nd Feb 2024 16:26
(Sharecast News) - London's stock markets finished in positive territory on Thursday, bolstered by upbeat performances from US AI chipmaker Nvidia and engine manufacturer Rolls-Royce.
Read moreIndivior planning to move primary listing to US, shares surge
22nd Feb 2024 08:26
(Sharecast News) - Indivior surged on Thursday after the opioid addiction treatment maker said it was planning to move its primary listing to the US.
Read moreLondon close: Stocks rise as UK inflation slows further
20th Dec 2023 15:05
(Sharecast News) - London's stock markets saw a notable upswing on Wednesday, driven by encouraging data revealing a greater-than-anticipated slowdown in UK inflation for November.
Read moreIndivior strikes agreement with Actavis over patent dispute
20th Dec 2023 07:26
(Sharecast News) - Indivior announced significant agreement in its ongoing patent dispute with Actavis Laboratories UT, a subsidiary of Teva Pharmaceuticals, on Wednesday.
Read moreLondon close: Stocks mixed ahead of Autumn Statement
20th Nov 2023 14:59
(Sharecast News) - London's stock markets saw a mixed performance at the close of trading on Monday, with Ashtead and Compass among the leading losers.
Read moreIndivior announces $100m share buyback
17th Nov 2023 12:15
(Sharecast News) - Pharma group Indivior has announced a $100m share buyback to reduce its issued shared capital and return cash to shareholders.
Read more